Use of histone deacetylase inhibitors for the care of Philadephia-negative myeloproliferative syndromes
The use of substances capable of inhibiting one or more enzymes of the histone deacetylase family (histone deacetylase inhibitors) for the therapeutic treatment of Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) is described. The dosage of the above-mentioned substances is significantly lower than that normally used for the care of other tumor syndromes and may be from 10 to 150 mg/day/patient.
1 - 12 . (canceled)
13 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, for use in the treatment of Philadelphia-negative myeloproliferative syndromes, characterized in that the daily dosage is from 10 to 150 mg per patient.
14 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride according to claim 13 , characterized in that it is in monohydrate form.
15 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride according to claim 13 , characterized in that it is in monohydrate crystal form.
16 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride according to claim 13 , characterized in that the daily dosage is from 30 to 120 mg per patient.
17 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride according to claim 13 , characterized in that the daily dosage is from 50 to 100 mg per patient.
18 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride according to claim 13 , characterized in that the Philadelphia-negative myeloproliferative syndrome is polycythemia vera.
19 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride according to claim 13 , characterized in that the Philadelphia-negative myeloproliferative syndrome is essential thrombocythemia.
20 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride according to claim 13 characterized in that the Philadelphia-negative myeloproliferative syndrome is primary myelofibrosis.
21 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride according to claim 13 , characterized in that the Philadelphia-negative myeloproliferative syndrome is secondary myelofibrosis.
22 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride according to claim 13 , characterized in that it is not administered in combination with other active principles.
23 . Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride according to claim 13 , characterized in that it is administered in combination with at least one other cytostatic active principle.